Retatrutide, a new dual agonist of the GLP-1 binding site and glucose-dependent released polypeptide (GIP) target, is demonstrating promising data in early patient assessments . Ongoing research https://thesocialroi.com/story11311953/retatrutide-emerging-research-and-potential-therapeutic-uses